Stockreport

NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021

NGM Biopharmaceuticals, Inc.  (NGM) 
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm Check Earnings Report
PDF NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patien [Read more]